Skip to main content
. 2023 Sep 8;8(17):e170513. doi: 10.1172/jci.insight.170513

Figure 5. Therapeutic effects of mocetinostat in mouse OA model.

Figure 5

(A) Fourteen-week-old mice underwent destabilization of the medial meniscus (DMM) or sham surgery, and mocetinostat or vehicle was injected i.p. 3 times a week starting 1 week after DMM surgery. Knees were harvested at 10 weeks postoperatively for histological analysis. (B) Results of von Frey test in mice at 10 weeks after surgery. Numbers of paw withdrawals from 5 stimulations per filament per mouse are shown. (C) Representative Safranin-O staining images for each group. Scale bars: 200 μm. (D) Summed Osteoarthritis Research Society International (OARSI) scores for the medial femoral condyle and the tibial plateau. (E) Meniscus histopathological scores. n = 14 for DMM + 10 mg/kg of mocetinostat, and n =15 for the other groups. For B, D, and E, *P < 0.05, **P < 0.01, Dunn’s test versus DMM + vehicle. All quantitative data are expressed as mean ± SEM, and results of Kruskal-Wallis test are shown in Supplemental Table 17.